Alector, Inc., a biotechnology company developing immuno-neurology therapies for the treatment of neurodegenerative diseases, has recently initiated a new Phase II trial in early Alzheimer’s disease (AD). The first participant has been dosed in the INVOKE-2 Phase II trial evaluating the efficacy and safety of AL002 in slowing disease progression in people with early AD. The study will enrol approximately 265 participants in US, Australia and Canada.
In addition, the company provided an update on its INFRONT-3 Phase III trial evaluating AL001 in people at risk for or with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). The first participant was dosed in July 2020 and the company is currently enrolling participants in US, Europe and Australia. Approximately 180 participants will be randomised to receive AL001 or placebo intravenously every four weeks.
https://www.neurologylive.com/view/first-dosage-al002-phase-2-early-alzheimer-disease
